A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

• DRUG: Ensifentrine 3 mg
• DRUG: Glycopyrrolate 42.5 mcg
• DRUG: Ensifentrine 1.5 mg
• DRUG: Ensifentrine 3 mg (marketed formulation)

Sponsor

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA